Corvus Pharmaceuticals financials
$11.76−0.93%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$19.3M | -$14.9M | -$12.2M | -$10.6M | -$10.3M | -$9.9M | -$8.1M | -$7.3M | -$5.9M | -$6.3M | -$5.7M | -$5.6M |
| Net income | -$18.0M | -$13.7M | -$12.3M | -$10.2M | -$8.0M | $15.2M | -$12.1M | -$40.2M | -$4.3M | -$5.7M | -$6.7M | -$6.0M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.19 | $-0.15 | $-0.15 | $-0.12 | $-0.10 | $-0.13 | $-0.18 | $-0.60 | $-0.07 | $-0.12 | $-0.14 | $-0.12 |
| EBITDA | -$19.3M | -$14.8M | -$12.2M | -$10.5M | -$10.2M | -$9.9M | -$8.1M | -$7.2M | -$5.9M | -$6.2M | -$5.6M | -$5.5M |
| Operating cash flow | -$15.4M | -$10.4M | -$9.2M | -$9.6M | -$5.8M | -$8.3M | -$8.5M | -$6.3M | -$5.5M | -$5.2M | -$5.2M | -$5.4M |
| Free cash flow | -$16.0M | -$10.5M | -$9.2M | -$9.6M | -$5.9M | -$8.3M | -$8.5M | -$6.3M | -$5.5M | -$5.2M | -$5.2M | -$5.4M |
| Diluted shares | 92.4M | 90.0M | 83.2M | 82.8M | 77.8M | 75.2M | 68.5M | 66.7M | 59.7M | 49.0M | 49.1M | 49.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $18.9M | $40.1M | $4.6M | $2.9M | $14.7M | $5.0M |
| Short-term investments | $196.3M | $196.6M | $52.2M | $62.8M | $59.7M | $39.2M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $239.3M | $253.2M | $71.1M | $80.5M | $89.5M | $59.4M |
| Total liabilities | $13.9M | $12.5M | $9.9M | $8.7M | $9.2M | $10.1M |
| Shareholders' equity | $225.3M | $240.7M | $61.2M | $71.8M | $80.2M | $49.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology